Article Information
History
- March 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Deirdre Kelly1,*,
- April A. N. Rose2,3,*,#,
- Thiago Pimentel Muniz1,
- David Hogg1,
- Marcus O. Butler1,4,
- Samuel D. Saibil1,4,
- Ian King5,6,
- Zaid Saeed Kamil5,6,
- Danny Ghazarian5,6,
- Kendra Ross4,
- Marco Iafolla1,4,
- Daniel V. Araujo1,7,
- John Waldron8,
- Normand Laperriere8,
- Hatem Krema9 and
- Anna Spreafico1,4,#
- 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
- 2Department of Oncology, McGill University, Montreal QC, Canada
- 3Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada
- 4Tumor Immunotherapy Program, Princess Margaret Cancer Center, Toronto, ON, Canada
- 5Department of Laboratory Medicine and Pathobiology, University of Toronto
- 6Princess Margaret Cancer Center, University Health Network
- 7Department of Medical Oncology, Hospital de Base, Sao Jose do Rio Preto, SP, Brazil
- 8Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto
- 9Ocular Oncology Service Krembil Research Institute, Princess Margaret Cancer Centre/University Health Network
- ↵#Corresponding Authors: Anna Spreafico, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 700 University Ave, 7-621 Toronto, M5G 1Z5, Ontario, Canada., Contact: anna.spreafico{at}uhn.ca, +1 416-946-4501 ext 2263, April A. N. Rose, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 700 University Ave, 7W-424 Toronto, M5G 1Z5, Ontario, Canada., Contact: april.rose{at}uhn.ca +1 416-946-4501 ext 5190
↵* Equal contribution
Posted March 02, 2021.
Development of a Metastatic Uveal Melanoma Prognostic risk Score (MUMPS) for use in patients receiving immune checkpoint inhibitors
